Travere Therapeutics, Inc.

NASDAQ:TVTX

Biotechnology

Healthcare
$50.24 +1.20%

+$0.65 today

Market cap
$4.82B
Beta
1.14
P/E (TTM)
-235.0
EPS (TTM)
-$0.23
52W Low $13.97High $55.99

Volume 0.84M

Average 2.31M

TVTX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Travere Therapeutics, Inc.NASDAQ: TVTX

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $23.44M rose 108.1% year over year, ahead of the +70.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 7.6% from the prior quarter. Over 3 fiscal years it compounded at +5.6% a year.

Context

  • Stock-based compensation amounted to 9.1% of revenue in FY2025, down 6.7 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +108.1% holds above the trailing-twelve-month pace of +70.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$23.44M+7.6% QoQ
Last fiscal yearDec 2025
$44.87M+21.6% YoY
LTMSep 2026
$72.84M+70.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+108.1%——
1 year+21.6%——
3-year CAGR+5.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
44.87M USD
Year-over-year change
+21.6%
4-year CAGR
+11.0%

Stock-Based Compensation vs competitors

How TVTX compares with its peers on the latest reported figures

  • TVTX's LTM Sep 2026 stock-based compensation of $72.84M is the largest of the 5 companies compared; the peer median is $18.74M.
  • Its year-over-year change of +70.9% is the 3rd highest of 5, against a peer median of +19.8%.
  • Stock-based compensation amounts to 11.2% of revenue for TVTX, versus a peer median of 101.4%.
TVTX Competitors Peer median
Stock-Based Compensation for TVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$72.84M +70.9%+5.6%11.2%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$25.03M +73.0%+248.9%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20.28M +92.0%+34.5%101.4%
PROKProKidney Corp.LTM Mar 2026$17.19M -38.8%-30.2%1933.5%
PHARPharming Group N.V.LTM Mar 2026$3.48M -33.4%—0.9%
Peer median (excluding TVTX) $18.74M+19.8%+34.5%101.4%

Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(217.29M)(331.47M)(376.33M)(320.63M)(25.55M)
Depreciation & Amortization12.75M20.72M38.53M43.56M60.74M
Deferred Income Tax00000
Stock-Based Compensation29.57M38.14M44.25M36.91M44.87M
Change in Working Capital80.78M875K(25.48M)(63.02M)(14M)
Accounts Receivables17.95M(1.43M)(11.3M)(6.04M)(27.82M)
Inventory117K(1.21M)(39.42M)(3.77M)5.02M
Accounts Payables2.47M2.06M24.76M(17.56M)(85K)
Other Working Capital60.24M1.46M481K(35.64M)8.89M
Other Non-Cash Items79.41M85.44M39.01M65.71M(28.28M)
Operating Cash Flow(14.79M)(186.29M)(280.02M)(237.48M)37.78M
Capital Expenditures(24.15M)(28.37M)(41.59M)(101.21M)(58.16M)
Acquisitions (Net)00000
Purchases of Investments(547.08M)(385.39M)(443.94M)(125.76M)(237.14M)
Sales of Investments433.6M381.99M334.58M326.33M323.6M
Other Investing Activities(19.05M)(28.97M)165.81M(40K)(404K)
Investing Cash Flow(137.62M)(32.55M)55.78M99.33M27.89M
Debt Repayment0104.93M00(68.9M)
Common Stock Issued224.93M19.55M191.2M134.74M37.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.75M(6.9M)27.55M4.68M(2.1M)
Financing Cash Flow231.68M117.57M218.75M139.42M(33.47M)
Effect of Forex Changes1.71M(2.79M)1.98M(913K)2.29M
Net Change in Cash80.98M(104.07M)(3.51M)359K34.5M
Free Cash Flow(38.94M)(214.66M)(321.61M)(338.69M)(20.37M)

Travere Therapeutics, Inc.

NASDAQ:TVTX

Intrinsic Alpha fair value

Locked

Current Price

$50.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.